Japan's MHLW authorises Regeneron and Sanofi’s Dupixent for COPD

Japan's MHLW authorises Regeneron and Sanofi’s Dupixent for COPD

This new option is intended for patients whose COPD is not sufficiently controlled with existing treatment. COPD is a chronic respiratory disease that progressively impairs lung function and The post Japan’s MHLW authorises Regeneron and Sanofi’s Dupixent for COPD appeared first on Pharmaceutical Business review.